Nymox Pharmaceutical (Nymox Pharmaceutical) Total Assets : $0.67 Mil (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Total Assets?

Nymox Pharmaceutical's Total Assets for the quarter that ended in Sep. 2023 was $0.67 Mil.

During the past 12 months, Nymox Pharmaceutical's average Total Assets Growth Rate was 35.70% per year. During the past 3 years, the average Total Assets Growth Rate was -3.90% per year. During the past 5 years, the average Total Assets Growth Rate was 27.40% per year. During the past 10 years, the average Total Assets Growth Rate was -5.20% per year.

During the past 13 years, Nymox Pharmaceutical's highest 3-Year average Total Assets Growth Rate was 85.80%. The lowest was -61.20%. And the median was -1.20%.

Total Assets is connected with ROA %. Nymox Pharmaceutical's annualized ROA % for the quarter that ended in Sep. 2023 was -881.70%. Total Assets is also linked to Revenue through Asset Turnover. Nymox Pharmaceutical's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Nymox Pharmaceutical Total Assets Historical Data

The historical data trend for Nymox Pharmaceutical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Total Assets Chart

Nymox Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

8.08

5.49

4.34

1.44

1.63

Nymox Pharmaceutical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial															3.14	1.63	0.58	0.27	0.67

Nymox Pharmaceutical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Nymox Pharmaceutical's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-0.482	+	2.107
	=	1.63

Nymox Pharmaceutical's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	-1.902	+	2.571
	=	0.67

Nymox Pharmaceutical (OTCPK:NYMXF) Total Assets Explanation

Total Assets is connected with ROA %.

Nymox Pharmaceutical's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-4.144	/	( (0.271	+	0.669)	/ 2 )
	=	-4.144	/	0.47
	=	-881.70 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Nymox Pharmaceutical's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0	/	( (0.271	+	0.669)	/ 2 )
=	0	/	0.47
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Nymox Pharmaceutical Total Assets Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel